고객센터
찾아오시는길

HOME > 회원마당 > 보도자료보도자료

ttMStBZWFiNVHMIkOR

johnansog | 2022.04.19 13:29 | 조회 212
September 18, 2018

Preferred Sources for Isolating Stem Cells in Dogs

A recent article reviewed potential tissue sources and applications for stem cell use in veterinary patients.
By Natalie Stilwell, DVM, MS, PhD
stem cell therapyStem cell research has increased significantly in human medicine over the past 20 years, and stem cells derived from sites including bone marrow and adipose tissue are now widely used to treat various diseases. Comparatively, stem cell therapy has been explored minimally in veterinary medicine. Researchers at the Konkuk University’s Center for Stem Cell Research in South Korea recently provided a reviewof mesenchymal stem cell (MSC) therapy in animals.

RELATED: 

Mesenchymal Stem Cells

MSCs differ from hematopoietic stem cells in that they can differentiate into osteoblasts, adipocytes, cardiomyocytes, chondrocytes, hepatocytes, and stem cells. MSCs can be isolated from the following adult, neonatal, and fetal tissues:
  • Bone marrow
  • Adipose tissue
  • Heart
  • Peripheral blood
  • Dermis
  • Umbilical cord blood (UBC)
  • Placenta
  • Amniotic fluid

MSC implantation has been explored for the treatment of a variety of disorders in animals, including atopic dermatitis, osteoarthritis, chronic kidney disease, spinal cord injury, and skin wounds. According to the study authors, an important next step is to determine an ideal tissue source for high yield of MSCs.
 

Umbilical Cord Blood

Collection of MSCs from UCB has been explored primarily in humans, sheep, and horses. Relatively few studies have examined UCB-MSC use in pet animals, including dogs.

While collecting UCB is noninvasive and associated with low morbidity, this source yields significantly fewer MSCs compared with other tissues, such as bone marrow. Human studies showed that UCB-MSC isolation into cell culture media had a low estimated success rate of 26%, but the likelihood of successful isolation relied heavily on obtaining sufficient blood volume. Similarly, UCB-MSC yield in horses, goats, and sheep reportedly increases with increasing blood volume. While some canine studies have successfully isolated MSCs from UCB volumes as low as 8 mL, the authors of the current study reported an average yield of only 1 mL of UCB with a 66% success rate for MSC isolation. Thus, UCB may prove to be an unreliable source of stem cells in canine subjects.

Another important consideration is that UCB can only be obtained during C-section in the dog, as the bitch typically consumes the placenta and umbilical cord during natural birth. While 1 study reported higher MSC yields from fetal heart tissue, this method is more invasive and raises ethical concerns. Therefore, the authors stated that alternative options to neonatal and fetal tissues should be explored.
 

Adipose and Reproductive Tissues

Adipose tissue can also be used for MSC collection, as cells from this source can differentiate into adipogenic, osteogenic, and chrondrogenic types. Interestingly, reproductive tissues also yield high numbers of MSCs. Although ovaries and testes are frequently discarded as medical waste during sterilization, both tissues are “proven to be potent and reliable sources of MSCs,” according to the authors. Both also have the same multipotent potential as do adipose-derived MSCs. Therefore, the authors recommended future use of reproductive and adipose tissues, rather than UCB, for MSC collection in veterinary medicine.   

 
Dr. Stilwell received her DVM from Auburn University, followed by a MS in fisheries and aquatic sciences and a PhD in veterinary medical sciences from the University of Florida. She provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting.

Sign up to receive the latest news in veterinary medicine.
보도자료
번호 제목 글쓴이 조회 날짜
147 인스코비 '줄기세포 활용 발모 촉진' 한·일 특허 취득 여섯시반 13468 2019.08.21
146 첨바법 통과로 탄력받은 '줄기세포 치료제' 개발 여섯시반 15279 2019.08.20
145 줄기세포 이식 후 생착률 높일 단서 찾았다 여섯시반 16482 2019.08.19
144 ‘첨단바이오법’ 제약바이오산업 성장엔진 될까 Ss 1811 2019.08.16
143 '줄기세포' 활용해 연골·조직 치료하는 시대 '눈앞' 여섯시반 16642 2019.08.14
142 韓·美·日 기업 `줄기세포·재생의료` 국경 뛰어넘는 투자 ss 17218 2019.07.01
141 1199건의 발의안 중 2건은 통과시켜야 한다고 합니다. 이희영 1711 2018.10.05
140 병원내 배양 치료는 불법이 아닌데..우리보다 수준낮은 일본까지 가다니.... 미래 4135 2018.10.02
139 개의 줄기세포 소스; 지방, 골수, 난자 미래 22311 2018.10.01
138 답글 BvYPRfZtKsDSfIEykm markus 181 2022.04.19
137 답글 ozSoFrnysqT johnanz 167 2022.04.19
>> 답글 ttMStBZWFiNVHMIkOR johnansog 213 2022.04.19
135 답글 eJqJsUwrGdZAgB ascvshjbm 189 2022.03.31
134 답글 wveXzVivCIdQkG hhphrtng 231 2021.11.18
133 답글 mqSVbumHSzsvXkFgi jbqufaac 161 2022.03.30
132 답글 izfrUerMNlhQsRy qtpqtwpo 243 2021.10.06
131 답글 kcDFYWyXVAhuLZCYBD srvwmy 231 2021.10.04
130 답글 OEcTWYoQAHrxHjiomoW vyxpchvtajv 180 2022.07.17
129 답글 RhzWUdlRRIwL obaymmugvt 154 2022.03.31
128 답글 fxjMaCWrpwIvcnqUWe wdfgpt 181 2022.03.31